Aurobindo Pharma completes acquisition of Lannett Company, USA
Aurobindo Pharma · Pharmaceuticals & Biotechnology
Key highlights
- Acquisition completed on June 29, 2026, after U.S. Federal Trade Commission approval on June 18, 2026
- Lannett Company Inc. now operates as Lannett Company LLC, a wholly owned subsidiary of Aurobindo Pharma USA Inc.
- Over 400 Lannett employees joined Aurobindo Pharma to strengthen its talent and operations
Why it's rated notable: The filing reports completed acquisition of Lannett Company, Inc. after FTC approval on June 18, 2026, but states no purchase value, so the level stays at medium.
Original filing
Announcement under Regulation 30 (LODR)-Updates on Acquisition
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Aerospace & Defense
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Aurobindo Pharma
- Acquisition / mergerNotableAurobindo Pharma reports unaudited Q2 and half-year results ended September 30, 2026
- Acquisition / mergerNotableAurobindo Pharma subsidiary Apitoria completes acquisition of A1 Biochem Group business
- Acquisition / mergerNotableAurobindo Pharma USA gets FTC approval to acquire Lannett Company LLC
- Acquisition / mergerNotableAurobindo Pharma receives US FTC approval for Lannett acquisition
Other acquisition / merger filings this fortnight
- IndiGrid Infrastructure Trust Q2 FY27 Earnings Conference Call Transcript Released
- Cubical Financial Services Ltd announces promoter reclassification post open offer
- Novus Loyalty Limited approves acquisition of AutoPe Payment Solutions via share swap
- Shish Industries Limited files Composite Scheme of Amalgamation proposal
- Jubilant Ingrevia Limited updates on acquisition of 40% stake in Zettaone Technologies
- NHC Foods approves quarter results, 99.98% Sachmaas Foods investment, two appointments
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.